Newsroom

06-17-21

CVRx® Announces First Clinical Procedure with a New Ultrasound-Guided Implant Approach, the Latest Advancement in Barostim™ for the Treatment of Heart Failure Symptoms

Read The Article
06-09-21

Response by Sex in Patient-Centered Outcomes With Baroreflex Activation Therapy in Systolic Heart Failure

Read The Article
04-07-21

Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States

Read The Article
01-05-21

CVRx® Appoints New Chief Marketing Officer and Vice President of European Sales and Marketing

Read The Article
12-03-20

CVRx® BAROSTIM Therapy Receives CMS Approval for Transitional Pass-Through Payment Status

Read The Article
11-18-20

CVRx® Announces New CFO and Acceleration of Barostim Therapy Commercialization Efforts

Read The Article
10-01-20

CVRx’s BAROSTIM NEO™ Receives CMS NTAP

Read The Article
08-30-20

Neuromodulation for Heart Failure, a New Therapeutic Frontier

Read The Article
08-29-20

See the Poster Here: Symptomatic Endpoint Responder Rates to BAROSTIM THERAPY

Read The Article
08-29-20

See the Poster Here: Quality of Life Response to BAROSTIM THERAPY

Read The Article
07-31-20

Does Neuromodulation Using Baroreflex Activation Therapy (BAT) have Potential Application in HFpEF?

Read The Article
07-21-20

News release: CVRx® Completes Enrollment of the BeAT-HF Phase III Randomized Clinical Trial, Continues to collect Morbidity and Mortality Outcomes

Read The Article
07-07-20

News release: CVRx® Raises $50 Million in New Equity Financing

Read The Article
07-01-20

Cardiology News: Women Thrive on Baroreflex Activation for Heart Failure

Read The Article
06-30-20

News release: CVRx® Announces Publication of BeAT-HF Clinical Study Results in the Journal of The American College of Cardiology

Read The Article
06-30-20

Read the Publication Here: BeAT-HF Clinical Study Results in the Journal of The American College of Cardiology

Read The Article
06-30-20

Editorial Accompanying the JACC Publication of BeAT-HF Clinical Study Results

Read The Article
06-23-20

News release: BAROSTIM™ NEO Associated with Very High Responder Rates in Women

Read The Article
06-19-20

See the Poster Here: BAROSTIM THERAPY in Patients with Heart Failure with a Reduced Ejection Fraction, Impact in Women

Read The Article
06-19-20

BAROSTIM NEO™ Reduces Heart Failure Symptoms for Patients with Atrial Fibrillation and/or LVEF < 25%

Read The Article
06-19-20

BAROSTIM NEO™ provides significant improvements in quality of life and exercise capacity, with high responder rates in women

Read The Article
05-07-20

BAROSTIM NEO™ Heart Failure Treatment Results in High Responder and Super-Responder Rates

Read The Article
05-07-20

BAROSTIM NEO™ Shows a Reduction in Serious Cardiovascular Events

Read The Article
05-07-20

BAROSTIM NEO™ Reduces Heart Failure Symptoms for Patients with or without Atrial Fibrillation

Read The Article
05-07-20

BAROSTIM NEO™ Reduces the Institutional Cost Burden of Heart Failure

Read The Article
08-16-19

News release: CVRx® Receives FDA Approval for World’s First Heart Failure Neuromodulation Device

Read The Article
05-27-19

BeAT-HF Pivotal Study Results Presented at ESC-HF

Read The Article
05-09-19

BeAT-HF Pivotal Study Results Presented at HRS

Read The Article
06-11-16

HOPE4HF 12 Month Data

Read The Article
11-19-15

News release: CVRx® Announces Expedited Access Pathway Designation by FDA

Read The Article
06-01-15

HOPE4HF Phase II Clinical Study Results

Read The Article
05-27-15

News release: CVRx® Barostim Therapy® for Heart Failure Clinical Trial Results Presented in the Late-Breaking Clinical Session of the ESC-Heart Failure 2015 Annual Conference

Read The Article
05-26-15

News release: CVRx® Barostim Therapy® for Heart Failure Clinical Trial Results Presented in the Late-Breaking Clinical Trial Session of the Heart Rhythm Society 2015 Annual Conference

Read The Article
03-18-15

BAT in HF 12 Month Data

Read The Article
03-17-15

News release: CVRx® Barostim Therapy™ for Heart Failure Clinical Trial Results Presented in a Featured Clinical Research Session of the American College of Cardiology Annual Conference

Read The Article
12-16-14

News release: CVRx® Granted Humanitarian Device Exemption Approval from FDA for Barostim neo legacy™ Hypertension Therapy Device

Read The Article
12-11-14

News release: CVRx® Granted CE Marking of the Barostim neo System™ for Conditional MRI Compatibility

Read The Article
09-29-14

News release: CVRx® Receives CE Mark Approval of the Barostim neo System™ for the Treatment of Heart Failure

Read The Article
07-28-14

BAT in HF Phase I Clinical Study Results

Read The Article
01-07-14

News release: Barostim Therapy™ Projected to be Cost-Effective in Treating Resistant Hypertension

Read The Article
08-25-11

News release: CVRx® Receives CE Mark Approval and Introduces New Implantable Device for Hypertension, the Barostim neo™

Read The Article
10-31-07

News release: CVRx®, Inc. Receives CE Mark Approval for Rheos® Baroreflex Hypertension Therapy™ System

Read The Article
09-18-06

News release: CVRx, Inc. Appoints Nadim Yared President and CEO

Read The Article

Images Available For Download

View / Download
circles